Thermo Fisher stock gains analyst support as UBS lifts target to 730 dollars

Published on 09/10/2026 at 23:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Thermo Fisher stock is in focus after UBS upgraded the shares to Buy on September 9, 2026 and raised its price target from 540 to 730 dollars. The stock traded around 606 dollars on September 9, leaving notable upside versus the new target and the 575-dollar level cited by Bernstein.

Aquarellbild eines gläsernen Forschungscampus an einem Fluss mit herbstlichen Bäumen — Aquarellmalerei symbolisiert Thermo Fisher Sci. US8835561023 mit gläsernem Forschungscampus entlang eines ruhigen Flusses im Herbst, Illustration mit AI erstellt.

Thermo Fisher Scientific Inc. stock (ISIN US8835561023) has drawn fresh attention after a high-profile analyst upgrade that significantly raised the upside scenario for the shares. As TheStreet reported on September 10, 2026, UBS upgraded Thermo Fisher from Neutral to Buy on September 9, 2026 and lifted its price target from 540 dollars to 730 dollars, putting the new target roughly 20 percent above the market level near 606 dollars on that day.

UBS upgrade and Bernstein contrast

According to TheStreet on September 10, 2026, UBS moved Thermo Fisher stock to Buy from Neutral and raised its price target by 190 dollars, from 540 dollars to 730 dollars, citing expectations that the company can sustain mid-single-digit organic revenue growth over the coming years as funding conditions in biotech and bioprocessing gradually improve.

The same article notes that the average 12-month target across 29 analysts stands around 638 dollars, meaning the UBS call sits about 92 dollars above the broader consensus and about 20 percent above the roughly 606-dollar share price seen on September 9, 2026, which underscores the degree of conviction in the new forecast.TheStreet

Providing a counterpoint, The Globe and Mail reported on September 10, 2026 that Bernstein maintains a Hold rating on Thermo Fisher and sets a price target of 575 dollars, implying more limited upside and positioning the shares below the consensus target of about 641 dollars cited in that note, which reflects a more cautious stance on valuation.

Recent earnings and guidance backdrop

The analyst calls build on a solid earnings backdrop. As MarketBeat summarized on September 10, 2026, Thermo Fisher last reported quarterly results for the period ended June 2026, delivering earnings per share of 6.03 dollars versus a consensus estimate of 5.71 dollars, a beat of 0.32 dollars per share, and revenue of 11.99 billion dollars compared with expectations of 11.71 billion dollars.

In the same report, MarketBeat notes that revenue for that June 2026 quarter increased 10.5 percent year over year, while the company posted a return on equity of 17.09 percent and a net margin of 15.04 percent, highlighting a combination of double-digit top-line growth and strong profitability.

Thermo Fisher also backed its outlook, with MarketBeat citing full-year 2026 earnings guidance in a range of 24.93 to 25.33 dollars per share and an average analyst expectation of about 25.13 dollars per share, which aligns closely with management’s targets and supports the valuation case being made by more optimistic houses such as UBS.

Dividend and shareholder returns

Beyond growth, Thermo Fisher continues to return capital to shareholders. According to the company profile data on Yahoo Finance as of September 10, 2026, Thermo Fisher has announced a quarterly cash dividend of 0.47 dollars per share, with an ex-dividend date on September 15, 2026 and the payment scheduled for October 15, 2026.

Putting that into annual terms, MarketBeat calculates that the 0.47-dollar quarterly dividend represents 1.88 dollars per share on an annualized basis, corresponding to a dividend yield of about 0.3 percent and a payout ratio of roughly 10.11 percent, which leaves ample room for reinvestment in research, acquisitions and capacity while still providing a modest cash return.

Current price, valuation and range

On the market side, Thermo Fisher stock continues to trade in the upper part of its recent range. A real-time quote from TechGraph shows Thermo Fisher Scientific (ticker TMO) at 602.71 dollars on the New York Stock Exchange with the market open, down 0.49 percent or 2.98 dollars on the session, based on a last known quote timestamp of September 10, 2026 at 11:28 p.m. GMT+0530.

In the same overview, TechGraph reports a day’s trading range between 594.82 dollars and 606.63 dollars and a 52-week range from 435.27 dollars to 647.00 dollars, with a market capitalization of 222.85 billion dollars and volume of about 876,940 shares as of that same date, illustrating that the current price sits closer to the 52-week high than the low and underlining the scale of the company in the healthcare equipment and services sector.

Looking at earlier trading, MarketBeat notes that Thermo Fisher stock was trading at 579.42 dollars at the beginning of 2026 and has since risen to around 603.43 dollars, a gain of roughly 4.1 percent year to date, which is modest but consistent with a large-cap healthcare name balancing cyclical lab demand with recurring consumables and services.

Strategic views and sector context

The UBS upgrade is not the only bullish voice. As Benzinga reported on September 10, 2026, CLSA analyst Michael Luo initiated coverage on Thermo Fisher Scientific on September 3, 2026 with an Outperform rating and a price target of 748 dollars, pointing to themes such as the gradual recovery of biotech funding, reshoring trends in bioprocessing and greater use of artificial intelligence in research and development as drivers of a potential return to organic growth above 5 to 6 percent in 2027.

In the same Benzinga piece, Thermo Fisher shares are noted as having risen 0.4 percent to settle at 605.69 dollars during the referenced session, adding another data point that the stock has been trading in the low 600-dollar zone while the new CLSA target implies more than 20 percent upside from that level, similar to the uplift envisioned by UBS.Benzinga

Sector moves also frame the daily trading tone. A healthcare sector snapshot from TradingKey on September 10, 2026 notes that the healthcare services and equipment sector was down about 0.69 percent, with Thermo Fisher Scientific stock itself reported as down 0.59 percent among the top turnover names, a reminder that short-term moves reflect broader risk sentiment as well as company-specific news.

Risks and upcoming checkpoints

While the earnings beat and raised targets support Thermo Fisher stock, the differing analyst views highlight valuation risk. With Bernstein’s 575-dollar target sitting below both the roughly 606-dollar trading level cited in the UBS-related report and the consensus around 638 dollars,The Globe and Mail it signals that some analysts see limited upside if growth slows or competitive pressures in instruments and reagents intensify.

Investors will also track upcoming corporate dates. The financial calendar information on Yahoo Finance lists an ex-dividend date on September 15, 2026 and a dividend payment date on October 15, 2026, followed by a scheduled event on October 21, 2026, giving shareholders concrete points at which new information or confirmations of the growth path may emerge.

Thermo Fisher stock near upper range

Based on the real-time data from TechGraph, Thermo Fisher stock’s reference price on the New York Stock Exchange is 602.71 dollars as of September 10, 2026, with the session showing a 0.49 percent decline on that quote and the shares trading between 594.82 dollars and 606.63 dollars intraday in a 52-week corridor stretching from 435.27 dollars to 647.00 dollars, underpinned by a market capitalization of 222.85 billion dollars.